Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DexCom
DXCM
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
IVZ Invesco
- 15.170
- -0.020-0.13%
Close Mar 31 16:00 ET
- 15.170
- 0.0000.00%
Pre 08:11 ET
6.79BMarket Cap12.86P/E (TTM)
15.260High14.795Low3.97MVolume14.970Open15.190Pre Close59.85MTurnover1.18%Turnover Ratio12.86P/E (Static)447.84MShares19.33252wk High0.64P/B5.09BFloat Cap13.49152wk Low0.82Dividend TTM335.23MShs Float27.063Historical High5.37%Div YieldTTM3.06%Amplitude4.530Historical Low15.092Avg Price1Lot Size
Invesco Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -8.52%1.19B | -55.63%316.9M | 23.81%438.4M | 47.63%489.1M | 44.99%-54.4M | 84.98%1.3B | 54.11%714.3M | -28.03%354.1M | 169.13%331.3M | 73.65%-98.9M |
| Net income from continuing operations | 547.32%752.4M | 135.78%238.7M | -38.59%103.6M | 19.16%195.9M | 29.19%214.2M | -118.17%-168.2M | -321.78%-667.1M | 0.24%168.7M | -24.90%164.4M | -30.19%165.8M |
| Operating gains losses | -85.81%14.9M | 2,700.00%15.6M | -73.79%8.1M | -111.44%-4.3M | -112.13%-4.5M | 404.81%105M | 99.19%-600K | -64.19%30.9M | 382.71%37.6M | 69.41%37.1M |
| Depreciation and amortization | -1.75%179.6M | -4.96%44.1M | 4.27%44M | -2.11%46.4M | -3.63%45.1M | -6.40%182.8M | -4.53%46.4M | -11.90%42.2M | -3.85%47.4M | -5.45%46.8M |
| Other non cash items | -14.10%-89.8M | -86.71%40.5M | 22.30%-137.3M | 113.44%28.9M | -367.07%-21.9M | 68.18%-78.7M | 101,500.00%304.8M | -203.61%-176.7M | -104.37%-215M | 109.74%8.2M |
| Change In working capital | 184.51%146.2M | 85.41%-35.1M | 54.12%314.1M | -26.66%191.5M | 18.37%-324.3M | 53.43%-173M | -255.33%-240.6M | -10.50%203.8M | 314.54%261.1M | 37.18%-397.3M |
| -Change in receivables | -28.75%319.7M | 16.79%-45.6M | -130.42%-32.4M | -93.03%32.6M | 616.41%365.1M | -50.84%448.7M | -128.71%-54.8M | -49.91%106.5M | 25.86%467.7M | -151.34%-70.7M |
| -Change in payables and accrued expense | 72.09%-173.5M | 105.65%10.5M | 256.12%346.5M | 176.91%158.9M | -111.08%-689.4M | 51.59%-621.7M | -416.11%-185.8M | 544.37%97.3M | 58.12%-206.6M | 57.59%-326.6M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -8.52%1.19B | -55.63%316.9M | 23.81%438.4M | 47.63%489.1M | 44.99%-54.4M | 84.98%1.3B | 54.11%714.3M | -28.03%354.1M | 169.13%331.3M | 73.65%-98.9M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 128.00%68.4M | 93.54%-16.9M | -58.05%27.9M | 463.99%344.7M | -731.43%-287.3M | 34.96%-244.3M | -90.12%-261.6M | 180.90%66.5M | -23.47%-94.7M | 157.52%45.5M |
| Net PPE purchase and sale | 57.94%-69.1M | 117.37%7M | 27.55%-28.4M | 42.83%-26.7M | 44.88%-21M | 14.83%-164.3M | 44.87%-40.3M | 37.48%-39.2M | -40.66%-46.7M | -59.41%-38.1M |
| Net investment purchase and sale | 107.16%10.7M | 89.50%-28.6M | -44.32%55.4M | 582.36%257.1M | -456.66%-273.2M | 30.56%-149.5M | -366.27%-272.3M | 340.92%99.5M | 7.14%-53.3M | 231.62%76.6M |
| Net other investing changes | ---- | ---- | ---- | ---- | ---- | --46.2M | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 128.00%68.4M | 93.54%-16.9M | -58.05%27.9M | 463.99%344.7M | -731.43%-287.3M | 34.96%-244.3M | -90.12%-261.6M | 180.90%66.5M | -23.47%-94.7M | 157.52%45.5M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -183.84%-1.66B | -255.85%-392.5M | -225.98%-409.1M | -315.96%-711.7M | 16.92%-148.3M | 39.46%-585.4M | 34.38%-110.3M | 52.78%-125.5M | 64.18%-171.1M | -222.78%-178.5M |
| Net issuance payments of debt | -467.40%-922.9M | -990.54%-197.7M | -4,036.73%-192.9M | -362.71%-498.1M | -199.13%-34.2M | 143.69%251.2M | 187.40%22.2M | 102.27%4.9M | 144.07%189.6M | -64.40%34.5M |
| Net common stock issuance | 57.71%-79.3M | -490.91%-26M | -674.36%-30.2M | 98.22%-2.7M | 26.35%-20.4M | 23.38%-187.5M | 4.35%-4.4M | 31.58%-3.9M | -7,873.68%-151.5M | 88.09%-27.7M |
| Cash dividends paid | -2.29%-608.3M | -1.74%-152M | -3.48%-154.5M | -0.86%-152.4M | -3.11%-149.4M | -4.04%-594.7M | -3.11%-149.4M | -3.04%-149.3M | -4.35%-151.1M | -5.77%-144.9M |
| Net other financing activities | 6.07%-51.1M | -178.87%-16.8M | -238.16%-31.5M | -0.69%-58.5M | 237.87%55.7M | -112.82%-54.4M | 213.24%21.3M | -77.45%22.8M | -158.57%-58.1M | -118.59%-40.4M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -183.84%-1.66B | -255.85%-392.5M | -225.98%-409.1M | -315.96%-711.7M | 16.92%-148.3M | 39.46%-585.4M | 34.38%-110.3M | 52.78%-125.5M | 64.18%-171.1M | -222.78%-178.5M |
| Net cash flow | ||||||||||
| Beginning cash position | 34.69%1.93B | 5.42%1.64B | 19.75%1.54B | 17.33%1.43B | 34.69%1.93B | -33.21%1.43B | 26.84%1.56B | 13.62%1.29B | -24.73%1.21B | -33.21%1.43B |
| Current changes in cash | -185.59%-403.2M | -127.02%-92.5M | -80.62%57.2M | 86.41%122.1M | -111.30%-490M | 173.69%471.1M | 116.98%342.4M | 104.93%295.1M | 115.19%65.5M | 54.51%-231.9M |
| Effect of exchange rate changes | -222.73%-32.4M | -249.27%-50.9M | 250.92%40.9M | -194.03%-6.3M | -226.77%-16.1M | 135.82%26.4M | -32.21%34.1M | 46.65%-27.1M | 113.40%6.7M | 154.74%12.7M |
| End cash Position | -22.55%1.5B | -22.55%1.5B | 5.42%1.64B | 19.75%1.54B | 17.33%1.43B | 34.69%1.93B | 34.69%1.93B | 26.84%1.56B | 13.62%1.29B | -24.73%1.21B |
| Free cash flow | -1.37%1.12B | -51.94%323.9M | 30.20%410M | 62.47%462.4M | 44.96%-75.4M | 122.71%1.14B | 72.64%674M | -26.65%314.9M | 216.57%284.6M | 65.69%-137M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
